Health
Phase I/II trial findings support use of CoronaVac vaccine in older individuals – News-Medical.Net
Researchers in China have reported phase I/II clinical trial findings showing that the vaccine candidate CoronaVac is well tolerated among older individuals and…
Researchers in China have reported phase I/II clinical trial findings showing that the vaccine candidate CoronaVac is well tolerated among older individuals and effectively generates antibody responses against severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
CoronaVac is an inactivated SARS-CoV-2 vaccine developed by Chinese pharmaceutical company Sinovac Life Sciences based in Beijing, China.
Writing in The Lancet Infectious…
-
Noosa News22 hours agoNew South Wales Blues left to pick up the pieces after fumbling a chance at State of Origin glory
-
Noosa News16 hours agoHelp to make recycling stick
-
Noosa News14 hours agoFormer Darling Downs Zoo employee sheds new light on horrific lion attack on teacher Joanne Cabban
-
Business16 hours agoAlphabet’s stock looks like a brilliant buy right now